STOCK TITAN

PEDEVCO 13D/A shows 56.0% SGK Trust stake; mergers, PIPE detailed

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

PEDEVCO (PED) Schedule 13D/A: The SGK 2018 Revocable Trust and Dr. Simon G. Kukes updated their beneficial ownership following the closing of PEDEVCO’s mergers and PIPE financing on October 31, 2025. The SGK Trust reports 51,791,325 shares with shared voting and dispositive power, representing 56.0% of the class, based on 92,519,352 shares outstanding as of November 4, 2025. Dr. Kukes reports 59,936,275 shares (including spouse holdings and options), equal to 64.8% of the class.

The amendment notes issuance of 10,650,000 shares of Series A Convertible Preferred Stock in the mergers and 6,363,637 Series A Preferred in the PIPE at $5.50 per share, with $35,000,004 in net proceeds. Each preferred share converts into 10 common shares after an information statement process under Rule 14c‑2; these conversion shares are not included in the reported beneficial ownership.

Corporate actions include a planned increase in authorized common stock to 300,000,000 and governance provisions tied to the Series A Preferred. Dr. Kukes resigned from the Board effective at closing. The filing also references support and shareholder agreements and future resale registration obligations for conversion shares.

Positive

  • None.

Negative

  • None.

Insights

13D/A lifts clarity on control and pending share conversions.

Dr. Simon G. Kukes reports beneficial ownership of 59,936,275 common shares, or 64.8%, while the SGK 2018 Revocable Trust reports 51,791,325 shares, or 56.0%, both based on 92,519,352 shares outstanding as of November 4, 2025. These figures exclude conversion shares from the newly issued Series A Preferred, which are not convertible within 60 days.

The mergers issued 10,650,000 Series A Preferred and the PIPE added 6,363,637 at $5.50 per share, with $35,000,004 in net proceeds. Each preferred converts at a 10‑to‑1 ratio after the Rule 14c‑2 information statement period, potentially adding material common share count via the automatic conversion mechanism.

Governance features include majority‑in‑interest consent rights for Series A Preferred on specified corporate actions and an increase in authorized common to 300,000,000. Actual impact depends on the information statement mailing and subsequent automatic conversion; subsequent filings may provide timing and resale registration details.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 92,519,352 shares of common stock issued and outstanding as of November 4, 2025, as confirmed by the Company's transfer agent on such date.


SCHEDULE 13D




Comment for Type of Reporting Person:
(1) Includes 3,000 shares of common stock held by Dr. Kukes' spouse. (2) Includes options to purchase 20,000 shares of common stock held by Dr. Kukes' Reporting spouse (10,000 of which have an exercise price of $1.39 per share, and 10,000 of which have an exercise price of $1.17 per share ) which have vested to Dr. Kukes' spouse, and/or which vest in the 60 days from the date of this filing. * Based on 92,519,352 shares of common stock issued and outstanding as of November 4, 2025, as confirmed by the Company's transfer agent on such date.


SCHEDULE 13D


SGK 2018 REVOCABLE TRUST
Signature:/s/ Simon G. Kukes
Name/Title:Simon G. Kukes, Trustee
Date:11/10/2025
KUKES SIMON G
Signature:/s/ Dr. Simon G. Kukes
Name/Title:Dr. Simon G. Kukes
Date:11/10/2025

FAQ

What stake did Dr. Simon G. Kukes report in PEDEVCO (PED)?

Dr. Kukes reported beneficial ownership of 59,936,275 common shares, representing 64.8% of the class, based on 92,519,352 shares outstanding as of November 4, 2025.

How many shares did the SGK 2018 Revocable Trust report for PEDEVCO (PED)?

The SGK Trust reported 51,791,325 common shares with shared voting and dispositive power, equal to 56.0% of the class, based on the same outstanding share count and date.

What preferred stock was issued in PEDEVCO’s merger and PIPE?

PEDEVCO issued 10,650,000 Series A Preferred in the mergers and 6,363,637 Series A Preferred in the PIPE at $5.50 per share.

What are the potential common shares from preferred conversions at PEDEVCO (PED)?

Each Series A Preferred share converts into 10 common shares after the Rule 14c‑2 information statement period; these conversion shares are not included in the reported ownership.

How much net cash did PEDEVCO raise in the PIPE financing?

The company reported $35,000,004 in net proceeds, used to pay liabilities related to the mergers and transaction expenses.

Did PEDEVCO (PED) change its authorized share count?

The charter amendments approved increasing authorized common stock to 300,000,000 shares.

Did Dr. Simon G. Kukes remain on PEDEVCO’s board?

No. He resigned as a board member effective upon the merger closing on October 31, 2025.
Pedevco

NYSE:PED

PED Rankings

PED Latest News

PED Latest SEC Filings

PED Stock Data

56.73M
26.78M
70.82%
2.45%
0.15%
Oil & Gas E&P
Crude Petroleum & Natural Gas
Link
United States
HOUSTON